Article

Travoprost punctum plug promising for glaucoma

Ocular Therapeutix Inc. has announced initial results of a feasibility study of a sustained-release travoprost-loaded punctum plug (OPX-TP1) for the treatment of glaucoma.

Bedford, MA-Ocular Therapeutix Inc. has announced initial results of a feasibility study of a sustained-release travoprost-loaded punctum plug (OPX-TP1) for the treatment of glaucoma.

The travoprost punctum plug was evaluated for the reduction of elevated IOP in subjects with open-angle glaucoma or ocular hypertension over a 30-day period. Twenty-six eyes were treated in 17 patients at the Singapore National Eye Center and the National University Hospital in Singapore. At day 3 post-insertion, mean IOP decreased by 5.5 mm Hg from baseline, and at day 30 post-insertion, mean IOP was 6.5 mm Hg below baseline.

Sustained-delivery punctum plugs may help to circumvent issues of patient non-compliance by eliminating the need for daily dosing of topical agents.

“This product has the ability to change [universally] the way we treat glaucoma,” said Shamira Perera, MD, principal investigator at the Singapore National Eye Center. “Sustained-release therapy could be advantageous to elderly patients who have difficulty administering drops, could help alleviate issues of non-compliance, and may be beneficial to anyone . . . with glaucoma who would prefer a life without the inconvenience of taking drops every day.”

Amar Sawhney, president and chief executive officer of Ocular Therapeutix, said phase II trials that will examine travoprost plugs for 60-day therapy (OTX-TP2) will be conducted later this year.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.